Novo Nordisk A/S

Case Overview
32 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/25/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Novo Nordisk A/S |
Court: | Court: District of New Jersey |
Case Number: | Case Number: 3:25cv00713 |
Class Period: | Class Period: 11/02/2022 - 12/19/2024 |
Ticker: | Ticker: NVO |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Novo Nordisk A/S (“Novo” or the “Company”) (NYSE:NVO) securities during the period from November 2, 2022, through December 19, 2024 (“the Class Period”). Investors have until March 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, a “68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectations of at least 25% weight loss. The press release further revealed that participant patients were permitted to modify their own dosage during the trail, and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. On this news, the price of Novo shares declined by $18.44 per share, from $103.44 per share on December 19, 2024, to close at $85.00 per share on December 20, 2024.
The complaint alleges that defendants, throughout the Class Period, failed to provide investors with material information concerning the true state of Novo’s REDEFINE-1 trial protocol; notably, that it was a “flexible protocol” which gave patients the ability “to modify their dosing throughout the trial.”
On December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, a “68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectations of at least 25% weight loss. The press release further revealed that participant patients were permitted to modify their own dosage during the trail, and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. On this news, the price of Novo shares declined by $18.44 per share, from $103.44 per share on December 19, 2024, to close at $85.00 per share on December 20, 2024.
The complaint alleges that defendants, throughout the Class Period, failed to provide investors with material information concerning the true state of Novo’s REDEFINE-1 trial protocol; notably, that it was a “flexible protocol” which gave patients the ability “to modify their dosing throughout the trial.”